Cargando…

Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone

Background: The European Group on Graves’ Orbitopathy (EUGOGO) recommends intravenous methylprednisolone (IVMP) as the first line treatment for moderate-to-severe active thyroid eye disease (TED). While many studies with varying doses of IVMP have reported improvements in inflammation, via clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Douglas, Raymond S, Batten, Ryan, Qadeer, Rana A, Cameron, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090106/ http://dx.doi.org/10.1210/jendso/bvab048.1718

Ejemplares similares

Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
por: Douglas, Raymond S., et al.
Publicado: (2022)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

Severe Thyroid Eye Disease in the US: A National Perspective
por: Singh, Gurkirpal, et al.
Publicado: (2021)

RF35 | PSAT262 Comparative Study of Hertel Exophthalmometer and Luedde Exophthalmometer Versus Computed Tomography for Measurement of Proptosis in Normal Subjects
por: Traiwanatham, Sirinapa, et al.
Publicado: (2022)

SAT-607 "Eye" Spy with My Big Eye: Thyroid Ophthalmopathy Secondary to Hashitoxicosis
por: Sharma, Pranjali, et al.
Publicado: (2019)

RF35 | PSAT269 Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase 2b Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Kahaly, George, et al.
Publicado: (2022)

Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology
por: Na, Dong Gyu, et al.
Publicado: (2017)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

SAT466 Inactive Thyroid Eye Disease Patient Journey
por: Cockerham, Kimberly, et al.
Publicado: (2023)

Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations
por: Shin, Jung Hee, et al.
Publicado: (2016)

2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations
por: Ha, Eun Ju, et al.
Publicado: (2021)

SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
por: Kaplan, Daniel, et al.
Publicado: (2020)

FRI541 The Epidemiology Of Thyroid Eye Disease In Olmsted County, Minnesota
por: Rachmasari, Kharisa N, et al.
Publicado: (2023)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

A Case of Thyroid Eye Disease Revealed During Secondary Adrenal Insufficiency
por: Ibrahim, Amira, et al.
Publicado: (2021)

FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
por: Douglas, Raymond, et al.
Publicado: (2023)

SAT-LB85 Use of Weekly Levothyroxine Regimen for Rapid Normalization of Thyroid Hormone Levels: A Case Report
por: Escudero, Jose Renato Martinez, et al.
Publicado: (2020)

SAT571 When Two Is Too Few: Bethesda IV Pathology On Repeat Thyroid Fine Needle Aspiration
por: Godar, Cassandra M, et al.
Publicado: (2023)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

Lyme Disease: An Autoimmunity-Based “Destructive Thyroiditis” or Just Another “Non-Thyroidal Illness”?
por: Dhliwayo, Nyembezi, et al.
Publicado: (2021)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

ODP590 Combined Orbital Irradiation and Systemic Steroids in the Management of Progressive Thyroid Eye Disease
por: Capellan, Maria Leonora, et al.
Publicado: (2022)

Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management
por: Barrio-Barrio, Jesús, et al.
Publicado: (2015)

MON-LB88 Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates
por: Livhits, Masha J, et al.
Publicado: (2020)

MON-LB84 Validation of TI-RADS (Thyroid Imaging, Reporting and Data System) Follow-Up Recommendations
por: Ravindra, Sindhura, et al.
Publicado: (2020)

OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
por: Gulbins, Anne, et al.
Publicado: (2023)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
por: Mohamed, Abubakr, et al.
Publicado: (2022)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

ODP498 Myocardial Ischemia precipitating thyroid storm diagnosed during recovery through Wellen's wave: An ECG for an eye
por: Patra, Shinjan, et al.
Publicado: (2022)

Awareness of EUGOGO guidelines and attitudes regarding smoking in Graves' orbithopathy in Croatia
por: Maja, Baretić, et al.
Publicado: (2021)

MON-607 Monitoring Thyroid Function in Patients on Amiodarone: A Review of Practice Patterns and Adherence to the Recommended Guidelines in a Health Care System
por: Davis, Ariane, et al.
Publicado: (2019)

SUN-419 Monitoring Thyroid Function Tests in Patients on Lithium: Adherence to Recommended Guidelines and Comparison of Practice Patterns in a Health Care System
por: Aliyeva, Sevil, et al.
Publicado: (2020)

LBODP101 Misleading FT4 Result In A Patient With Hashimoto's Thyroiditis
por: ALShehri, Sara Mohammed, et al.
Publicado: (2022)

Can Thyroidectomy Improve Quality of Life in Patients With Hashimoto’s Thyroiditis?
por: Latif, Summaya A, et al.
Publicado: (2021)

ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Janes, Jonathan, et al.
Publicado: (2022)

Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
por: Douglas, Raymond S.
Publicado: (2018)

The Importance of the 2015 American Thyroid Association Guidelines for Adults with Thyroid Nodules and Differentiated Thyroid Cancer in Minimising Overdiagnosis and Overtreatment of Thyroid Carcinoma
por: Leite, Valeriano
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_033kd8imk1l42af42eq3p8atpd